OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 1.59% over the past week and 14.80% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 10.88% upside.

Holdings Analysis: VTI's top five holdings with the highest upside potential include Cibus, FibroBiologics, and Biodesix, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies.

VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 0.69% over the past week and 14.80% year-to-date, with a Moderate Buy consensus from analysts and a price target suggesting a 12.21% upside.

Holdings Analysis: VTI's top five holdings with the highest upside potential include Biodesix and Cibus, while those with the greatest downside risk include Wolfspeed and Opendoor Technologies; overall, VTI's Smart Score indicates it will likely perform in line with the market.

VTI Stock Performance: The Vanguard Total Stock Market ETF (VTI) has increased by 1.15% over the past week and 14.92% year-to-date, with a Moderate Buy rating from analysts and a price target suggesting an 11.18% upside.

Holdings Analysis: VTI's top five holdings with the highest upside potential include Cibus and Biodesix, while those with the greatest downside risk include Wolfspeed and GoPro.

Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.

Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.

Trial Progress and Financial Outlook: OnKure Therapeutics is making progress in its PIKture-01 trial, with plans to report additional data in late 2025. The company has $96.7 million in cash, expected to fund operations through Q4 2026.

Development of New Candidates: OnKure is advancing its PI3K franchise, aiming to announce a pan-mutant selective development candidate by Q2 2025, while also reporting positive preliminary results from the ongoing trials of its lead drug, OKI-219.

Analyst Rating Changes: Various Wall Street analysts have adjusted their price targets for several companies, with Citigroup lowering AvePoint's target from $18 to $16 while maintaining a Neutral rating, and BMO Capital raising Protagonist Therapeutics' target from $62 to $72 with an Outperform rating.

Stock Performance Updates: Other notable changes include Stifel cutting DarioHealth's target to $2 but keeping a Buy rating, and Morgan Stanley increasing Gilead Sciences' target to $130 while maintaining an Overweight rating.